Efficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study
Abstract Objective This study aims to assess the efficacy and safety of RC48 in combination with PD-1 inhibitors for patients diagnosed with locally advanced or metastatic urothelial carcinoma (mUC). Methods A retrospective analysis was performed on clinical data from 53 patients with locally advanc...
Saved in:
| Main Authors: | Tiantian Zhang, Shuo He, Lu Tao, Mengting Shi, Yue Wu, Yuanyuan Guo, Rui Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-04-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02362-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
by: Huaixi Ge, et al.
Published: (2025-02-01) -
RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study
by: Daining Wang, et al.
Published: (2025-04-01) -
The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer
by: Jingxian Li, et al.
Published: (2025-01-01) -
Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real‐World, Ambispective RAVE‐Bladder Study
by: Ilya Tsimafeyeu, et al.
Published: (2025-02-01) -
Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study
by: Xu Chen, et al.
Published: (2025-07-01)